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SUMMARY
The European Regional Office of WHO has targeted measles for elimination from the region in
2007. Large national, age and sex stratified serological surveys of measles antibody were
conducted in seven Western European countries from 1994–8 as part of the European Sero-
epidemiology Network. Three patterns were observed in the country-specific measles
seroprofiles, ranging from (very) low susceptibility (four countries) to high susceptibility (one
country). Susceptibility levels amongst 2–4-year-olds ranged from 2–9 to 29–8%, in 5–9-year-
olds from 2–5 to 25% and 10–19-year-olds from 2–1% to 13–9%. A country’s susceptibility
profile was highly associated with vaccine coverage for the first dose. First dose coverage
ranged from 91 to 97–5% for low susceptibility countries, 75 to 85% for intermediate
susceptibility countries and 55% for the high susceptibility country. Only the high susceptibility
country still reports epidemic measles. In low susceptibility countries, which have achieved or
are very close to measles elimination, the priority will be to maintain high MMR vaccine
coverage in all geopolitical units for both vaccine doses. In moderate susceptibility countries
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there is still some endemic transmission, but also risk of outbreaks as pools of susceptibles
accumulate. In the high susceptibility country the priority will be to increase infant vaccine
coverage and reduce regional variation in coverage levels.
INTRODUCTION
Measles is an acute viral infection of very high
transmissibility, which resulted in almost universal
infection during early childhood in the pre-
immunization era [1]. Due to the availability of a
highly efficacious vaccine for over 30 years, the
implementation of measles control programmes has
been a very cost-effective intervention in both
developing and developed countries [2] and many
countries have now moved from a control to an
elimination phase [3]. The WHO Regional Office has
targeted measles for elimination from Europe by year
2007 [4].
A variety of vaccination strategies have and are
being used in an attempt to interrupt transmission,
including two-dose vaccination programmes and a
one-dose programme with catch-up campaigns [5].
The success of a vaccine programme, especially
moving from the control to the elimination phase,
requires the identification of susceptible age groups.
This depends upon high quality measles surveillance
data, including accurate age-specific incidence data
and measles vaccine coverage levels. Population-based
serological surveys measure the population suscep-
tibility profile, providing a more direct measure of a
vaccination programme’s impact. The age-group
specific susceptibility levels needed to achieve measles
control in Europe have now been established [6].
To determine if these susceptibility targets have
been reached, comparability of serosurvey results is
essential. Internationally, a variety of serological
methods have been used to collect sera and measure
measles antibody levels. The European Sero-Epi-
demiology Network (ESEN) was established to co-
ordinate and harmonize the serological surveillance of
immunity to several vaccine preventable diseases
including measles [7]. We present the standardized
results of national serological surveys from seven
Western European countries performed with com-
parable designs, providing a unique opportunity not
only to compare the serological and epidemiological
impact of a variety of measles vaccination schedules
and coverage levels, but also to assess progress
towards measles control and elimination in Western
Europe.
METHODS
Serum survey collection
Seven of the member countries of ESEN undertook
collection and testing of several thousand sera
specimens between 1994 and 1998 (Denmark, England
and Wales, Finland, France, Germany, Italy, The
Netherlands). In Denmark, sera collection for those
less than 6 years was undertaken in 1997–8, those aged
6–16 years was performed in 1994. The minimum
number of sera to collect per age group was
determined from power calculations using age specific
estimates of seroprevalence of antibody to various
vaccine preventable infections. The number of sera
collected per country ranged from 2766–8303.
The sources of sera used have been described
previously [8]. Two methods of sampling were used:
population based random sampling and use of
residual sera collected during routine laboratory
testing. In both cases, samples were collected from a
variety of geographical locations within each country
to provide a reasonably representative estimate of the
general population immunity. For each specimen, the
age, sex and year of collection were gathered plus
some regional data in Italy (North and South) and
Germany (East and West). The sole exclusion criterion
was sera collected from individuals with known
immune deficiencies.
Standardization: panel distribution and testing
To achieve quantitative comparability of assay results
between countries, the results of measles antibody
testing were standardized using a methodology de-
veloped as part of the ESEN project. This has been
described in detail previously [9]. Briefly, the process
involved the distribution of a panel of 150 negative,
low positive and positive sera for measles antibody by
a reference laboratory (Statens Serum Institut,
Copenhagen, Denmark) to the national laboratory in
each participating country. The panel was tested in
each national laboratory by their usual quantitative
enzyme immunoassay (EIA). Standardization
equations were calculated by regressing the local
results of panel testing in these countries against those
of the reference laboratory.
251Seroepidemiology of measles in Europe
Table 1. Age-specific percentage of seronegatiity for measles antibody in seen countries of ESEN and WHO
target
Country 2–4 years 5–9 years 10–19 years 20–39 years "fl 40 years
WHO Target ! 15% ! 10% ! 5% ! 5% ! 5%
Low susceptibility
FI 2–9% 2–5% 2–1% 1–4% 0–3%
NL 4–0% 4–7% 5–1% 1–8% 0–1%
UK 14% 8–8% 4–7% 5–1% 3–3%
FR 10–3% 9–9% 5–0% 1–2% 0–2%
Intermediate susceptibility
DK 24–2% 10–5% 4–7% 0–5% 0–5%
DE 23–1% 9–1% 7–5% 2–0% 0–5%
High susceptibility
IT 29–8% 25–0% 13–9% 4–3% 1–3%
Main serum survey testing
The main national serum survey was tested using the
same validated assay method. The country-specific
standardization equations were used to convert the
local quantitative results of the serum survey into
standardized reference laboratory unitage. The ref-
erence laboratory cut-off range (the EIA of Behring
assay) was used to classify these standardized quan-
titative results as positive, low positive or negative
(negative ! 150 mI U; low positive 150–350 mI U;
positive " 350 mI U). Unless otherwise stated, the
low positives were reclassified as positive.
As detailed in a paper describing the standardiza-
tion process, these values are at variance with the
unitages produced by other EIAs [9], thus the
results reported in this paper may differ slightly
from percentages reported elsewhere by individual
countries.
Vaccine programme structure and coverage
A questionnaire was distributed to all participating
countries to gather data on measles vaccine pro-
gramme organisation, historical vaccine coverage and
age-specific incidence of measles. Some of these results
have previously been reported [5].
Coverage estimation
A number of countries had inadequate or incomplete
coverage data on their vaccination programmes.
Estimates of the level of MMR vaccine coverage in
each country were derived from the ESEN serological
data [10]. This method utilises serological data at the
individual level to estimate the proportion of indi-
viduals of a given age who have been vaccinated and
the proportion infected with each of the three viruses.
By assuming that seroconversion to each of the three
antigens is independent within an individual and that
the viruses circulate independently of each other (so
the chances of being infected are independent), then
the probability of an individual of a given age being in
any of the eight mutually exclusive serological groups
(ranging from positive to all three to negative to all
three) can be described in terms of vaccine coverage
(in that cohort), vaccine efficacy for each of the three
components of the vaccine, and the cumulative
infection rates. These parameters are then estimated
using maximum likelihood. Estimates of monovalent
measles vaccine coverage prior to the introduction of
MMR were made from official statistics or by
questionnaire distributed to the ESEN country co-
ordinators [5].
RESULTS
Three patterns were observed in the country-specific
measles seroprofiles based on the WHO Regional
Office for Europe age-specific susceptibility levels
recommended to interrupt measles transmission
(Table 1; Appendix). These patterns ranged from low
susceptibility to high susceptibility. In none of the
seven countries was a significant sex difference
observed in the proportion seronegative in any of the
age groups (data not shown). For all countries, the
proportion of low positives was highest in those age-
cohorts in whom a large proportion were vaccinated
at least a few years ago (Fig. 1).
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Fig. 1. For legend see facing page.
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Low susceptibility countries
The group with low susceptibility includes Finland,
The Netherlands, France and England and Wales.
Table 1 shows that for Finland and The
Netherlands, the age-specific susceptibility levels are
well below the WHO target levels, further illustrated
by their respective age specific population seroprofiles
(Fig. 1). These figures show the proportion in each age
class with measles antibody (seropositive and equivo-
cal) and the proportion estimated to have vaccine
derived immunity. Below the figure the vaccine
programme in place for each age-cohort is shown. In
both countries, the proportion seronegative in any
agegroup (particularly in 1–20-year-olds) does not
exceed 5% (except 5–1% for 10–19-year-olds in The
Netherlands). In Finland, the proportion seronegative
is even lower than in The Netherlands (Table 1).
Virtually all those seropositive for measles antibody
under 20 years of age are estimated to have vaccine
derived immunity (Fig. 1). This is a reflection of the
introduction of measles vaccine approximately 25
years ago, followed by a two-dose MMR programmes
with very high coverage in both countries in the early
1980s. Reported vaccine coverage has been slightly
higher (97% for both doses) in Finland compared to
The Netherlands (94% for the first dose and estimated
to be similar for the second dose). Finland in addition
undertook a catch-up campaign targeted at 2–6-year-
olds, when the MMR programme was initially
introduced. Both countries from the serosurvey seem
to be apparently near the elimination of measles. In
Finland and until recently The Netherlands (see later),
there has been an extremely low reported incidence of
confirmed clinical cases (Fig. 2).
The United Kingdom and France have recently
joined the low susceptibility countries. The population
susceptibility levels are higher then those in The
Netherlands and Finland and only just within the
WHO recommended targets (Table 1). The majority
of seropositives under the age of 18 years at the time
of the serosurvey in the United Kingdom are estimated
to have vaccine-derived immunity (Fig. 1). This is a
reflection of the vaccination programme history:
single dose MMR vaccine was introduced in 1988,
with reported vaccine coverage increasing from 80%
to around 90% only recently. However, a mass
Fig. 1. Seroprevalence of measles antibody for each ESEN member country (+ antibody positive, * low antibody positive),
the estimated proportion of each age-group vaccinated (>) and their vaccine history by age-group (in years). Age-group
vaccine history defined below each figure: measles, MMR1 (single dose mass infant vaccination programme), MMR2 (second
dose mass vaccination programme), catch-up (one-off targeted vaccination programme).
measles-rubella catch-up campaign was conducted in
November 1994 targeted at 5–16-year-olds (with
reported 92% coverage), and a second dose of MMR
introduced at the end of 1996 for 4-year-olds. The
reported incidence of clinical measles fell below
10}100000 in 1996 (Fig. 2), although only a small
proportion (10%) of these rash-illness cases are
laboratory confirmed as measles cases [11].
For France, the serological profile resembles that of
the United Kingdom. The seronegativity level
amongst 2–9-year-olds is about 10% and 5% for
10–19-year-olds (Table 1). France introduced a single
dose MMR vaccination in 1983. A second dose was
introduced in 1996 initially for 11–13-year-olds and
then changed to 3–6-year-olds the following year (Fig.
1). Measles epidemic cycles have been interrupted in
France since 1987. The incidence rate of measles
estimated from a network of sentinel GPs, had levelled
at approximately 100}100000 inhabitants between
1993 and 1997, and has fallen down to 32}100000
population in 1998 (Fig. 2).
Intermediate susceptibility countries
The group with intermediate susceptibility includes
Denmark and Germany, as in both these countries,
susceptibility levels are not within the WHO targets.
In Denmark, no measles vaccination (either with
MMR or single antigen measles vaccine) occurred
until 1987. A two-dose MMR vaccination programme
was introduced in this year (at age 15 months and 12
years). A catch-up targeted at children aged 2–10
years was also conducted at this time. From the
serological survey, 24% of 2–4-year-olds remain
seronegative and 10% of 5–9-year-olds (Table 1).
This falls to below 5% for 10–19-years-olds. Virtually
all those who are seropositive under 5 years of age,
probably acquired immunity through vaccination
(Fig. 1). A large proportion of 5–12-year-olds were
naturally infected, with an increase in the proportion
with vaccine derived immunity at 13 years of age with
the second dose of MMR. We do not know what
proportion of these had already experienced natural
infection earlier in life. Epidemic transmission has
been interrupted and the reported measles incidence
has been below 3}100000 since 1992 (Fig. 2).
Germany is the other intermediate susceptibility
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Fig. 2. Reported incidence of measles infection per 100000 population in six ESEN countries.
country (Table 1). The serological survey shows that
a high proportion of 2–4-year-olds are seronegative
and a higher proportion of 10–19-year-olds compared
to Denmark (Table 1). There is also a significant
difference in the age-specific seropositivity between
sera taken from former East and West Germany (Fig.
1). The vaccination programme history differs be-
tween the Eastern and Western parts of the country.
In West Germany, recommendations for measles
vaccination were introduced in 1975, followed by
single dose MMR vaccination in 1980. In East
Germany, compulsory infant monovalent measles
vaccination was started in 1970, followed by a
monovalent two-dose strategy in 1986. The reported
coverage in the former GDR was " 95%, whereas the
estimated coverage in West Germany was only
60–80%. After re-unification in 1991, a two-dose
MMR vaccination programme was recommended
throughout Germany, with the second dose for 6-
year-olds. No data are available on the incidence of
measles infection in Germany.
High susceptibility countries
Italy is the only country belonging to the high
susceptibility group. The proportion seronegative
amongst 2–4-year-olds and 5–9-year-olds is approxi-
mately 30 and 15% in 10–19-year-olds, considerably
higher than the low and intermediate susceptibility
countries (Table 1). Fifty percent of children aged 2–6
years were estimated to have vaccine derived im-
munity in 1996, although a large proportion even in
the younger age-classes probably acquired immunity
through exposure to wild virus (Fig. 1). Voluntary
vaccination with one dose of MMR was introduced in
1979 and there are large reported regional differences
in coverage (ranging from 26–88% from the South to
North) [12], although there was no significant
difference in the seroprofile by region (data not
shown). Indeed, measles still remains epidemic in
Italy, with regular 4-yearly epidemic cycles reported
(Fig. 2).
DISCUSSION
ESEN is the first study to our knowledge to present
comparable results of population-based measles sero-
surveillance studies from several countries, with all
participants having undertaken collections of large
samples of sera, tested with standardized method-
ology.
The study confirms that high vaccine coverage is the
most important factor needed to interrupt and control
measles transmission. A country’s susceptibility
profile was highly associated with vaccine coverage
for the first dose. With the exception of Denmark, the
susceptibility level was directly associated with the
reported incidence of measles [5]. Both Finland and
The Netherlands have had high vaccine coverage for
over 10 years, with an interruption of epidemic
measles, so virtually no immunity in the younger age
groups is naturally acquired and all is vaccine derived.
Finland has moved from the control to the elimination
phase with no serologically confirmed measles cases
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identified since 1996 [13, 14]. In The Netherlands the
annual number of notified measles cases has decreased
from 472 (3–1}100000) to 57 (0–37}100000) over the
period 1992–6 [15]. Factors besides the slightly lower
vaccine coverage to explain this continued measles
circulation in The Netherlands could include the more
elaborate catch-up conducted in Finland, more im-
portation of measles virus in The Netherlands and
circulation of wild virus in the clusters of religious
groups who refuse vaccination. Indeed, in 1999–2000,
an outbreak of measles occurred in The Netherlands
with almost 3000 cases and 3 measles related deaths.
The outbreak started in a school where most children
were not vaccinated for religious reasons, and spread
to religious groups around the country who refrain
from vaccination [16].
Other countries, such as the United Kingdom and
France, have recently undertaken specific inter-
ventions to improve vaccine programme performance
and thus move from the intermediate to the low
susceptibility group. In the United Kingdom, coverage
with single-dose monovalent measles vaccine prior to
1988 was only adequate to reduce the incidence of
measles infection, but not to immunize all of each
birth cohort. After, a period of time, susceptibles had
accumulated amongst older age groups. With pre-
dictions of a measles epidemic, a national catch-up
campaign was conducted in November 1994 targeted
at 5–16-year-olds [17], followed by the introduction of
a second dose of MMR in 1996. Unfortunately,
routine vaccine coverage levels in the United Kingdom
have not been maintained due to some public concern
over vaccine safety. In France, modelling undertaken
through the ESEN project showed the likelihood of a
large outbreak of measles in the younger age-groups
without an increase in vaccination coverage or a
catch-up campaign. Thus the low susceptibility
observed in the 2–4-year-olds most likely reflects this
recent catch-up following a media campaign in mid-
1997 together with a simultaneous lowering of the age
of the second dose to between 3 and 6 years. However,
available data show that routine vaccination coverage
of children under 2 years of age has not increased.
Thus France’s position as a low susceptibility country
is also a little misleading, as current levels of vaccine
coverage will result in a re-accumulation of
susceptibles.
The intermediate susceptibility countries include
Denmark and Germany. The low incidence of notified
measles in Denmark compared to the relatively high
level of susceptibility in under-10-year-olds suggests a
honeymoon phase (or alternatively important under-
notification). This term describes the period after the
introduction of mass vaccination with moderate
coverage during which disease incidence is low. As
coverage levels are only moderate, there is an
accumulation of susceptibles over time, until the
epidemic threshold is surpassed and an outbreak
occurs. A catch-up campaign in conjunction with
improved coverage of both the first and second doses
would prevent this phenomenon. In Germany, the
gradual decrease in seronegativity observed between
the age of 2 and 5 years is probably due to several
factors : the impact of second dose MMR introduced
in 1991; closing vaccination gaps during the legal
medical examination before school entry of 6-year-old
children and natural infection as occurred during the
epidemic outbreak in 1996 [10, 18]. Unfortunately, the
lack of corroborating evidence regarding coverage
and the absence of measles surveillance data hampers
further investigation.
The low vaccine coverage in Italy has reduced, but
not completely stopped viral circulation amongst
infants, resulting in the accumulation of a pool of
susceptibles amongst older children and adults com-
pared to the prevaccination era. By the age of 10
years, 20% of the population are still seronegative,
considerably more than the 8% observed in the
prevaccination era [19]. Vaccination has thus resulted
in a shift in the mean age of infection – with 13–18%
of measles cases over 10 years of age during the 1970s
compared to 40–50% in recent years [20]. A later age
of infection is associated with more severe compli-
cations [21].
Routinely collected data from the United Kingdom
show that those who receive a first dose are more
likely to receive a second compared to those who are
unvaccinated. If this pattern is repeated elsewhere in
Europe, the initial priority in measles control is to
achieve high first dose coverage. Once control is
achieved, a second dose and}or catch-up can be
introduced to immunize primary vaccine failures and
those who have failed to receive their first dose (22,
23).
The proportion of low antibody positives for all
countries was highest in the vaccinated age groups
and lowest in the age groups " 30 years and partly in
the age-groups of recently vaccinated children (1–3 or
4-years-old). This difference is probably explained by
lower antibody titre after vaccination (or more rapid
antibody loss) than after natural infection [24]. A
cohort study in Finland demonstrated that vaccine
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induced measles antibodies declined more rapidly in
the absence of natural boosting than expected [25]. It
will be important to both monitor the level and
quality of vaccine-induced antibodies in the popu-
lation and continue epidemiological surveillance in a
period of decreasing opportunity for natural boosting.
Furthermore, with vaccinated mothers living in a time
of decreased opportunity for natural boosting, there is
a need to monitor the persistence of maternal
antibodies in infants, as this may influence the age of
first vaccination. Variability observed in the pro-
portion of seropositive infants in ESEN is partially a
reflection of inter-country differences in the age (in
months) of sampling, information that was not
routinely collected as part of the project, thus limiting
any interpretations.
The study also enabled an observation of the effect
of the second dose of MMR on population immunity
levels in some countries. The effect could not be
studied in United Kingdom due to the narrow time
frame between data collection and the introduction of
the second dose and in Italy no second dose is given.
However, in Finland and The Netherlands, no
significant reduction was observed in the proportion
seronegative in those cohorts eligible for a second
dose compared to those receiving one. This ob-
servation could be due to the very high first dose
coverage. However, a 12-year follow-up study con-
ducted in Finland, found that after a brief increase in
IgG antibody titre after the second dose, population
antibody levels declined to pre-booster dose levels
[26], suggesting that population serosurveillance may
be limited in monitoring the impact of a second dose
of MMR.
We can conclude that low susceptibility countries
have achieved or are very close to measles elimination.
Their continuing priority is to monitor coverage,
strengthen disease surveillance with laboratory con-
firmation of suspect cases and to maintain high
vaccine coverage in all geopolitical units for both
vaccine doses. In moderate susceptibility countries,
success in measles control is being achieved, but there
is still endemic transmission and}or the risk of
outbreaks as pools of susceptibles accumulate. Vac-
cine coverage assessment and disease surveillance may
need to be strengthened (or introduced) and catch up
campaigns may be needed to fill population sus-
ceptibility gaps. In the high susceptibility
country – the priority is to increase infant vaccine
coverage and reduce regional variation in coverage
levels. Introduction of a second dose is only recom-
mended once a coverage of " 80% is reached.
Serosurveillance can provide an important tool to
support the evaluation of country vaccination pro-
grammes. The utilization of this data in mathematical
models allows a quantitative evaluation of alternatives
to determine the most appropriate vaccination strat-
egy. Using these tools, the WHO European regional
target of eliminating measles from the region by the
year 2007 can still be achieved.
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Appendix: Measles antibody serological results by
age class in seen ESEN countries
1. Denmark (collected 1994–8)
Age Negative
Low
positive Positive Total
0 14 1 23 38
1 48 2 46 96
2 23 74 97
3 25 2 74 101
4 17 1 53 71
5 8 3 37 48
6 10 4 98 112
7 7 6 87 100
8 9 4 86 99
9 14 4 80 98
10 12 6 82 100
11 9 5 86 100
12 6 2 91 99
13 3 1 95 99
14 2 5 92 99
15 1 99 100
16 5 1 94 100
17 1 38 39
18 1 46 47
19 1 53 54
20–24 1 2 196 199
25–29 2 199 201
30–34 1 198 199
35–39 201 201
40–49 1 207 208
50–59 1 200 201
60› 1 1 198 200
Total 219 54 2833 3106
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2. England and Wales (collected 1996)
Age Negative
Low
positive Positive Total
0 0 0 0 0
1 12 2 20 34
2 11 6 57 74
3 14 4 62 80
4 8 8 66 82
5 6 12 57 75
6 5 9 57 71
7 4 12 54 70
8 13 16 60 89
9 6 20 55 81
10 2 20 69 91
11 1 6 56 63
12 2 9 58 69
13 5 12 56 73
14 6 6 77 89
15 5 9 66 80
16 2 14 66 82
17 2 16 69 87
18 7 10 83 100
19 7 11 82 100
20–24 15 22 146 183
25–29 9 17 153 179
30–34 11 4 167 182
35–39 2 6 172 180
40–49 4 7 170 181
50–59 3 2 181 186
60› 11 1 173 185
Total 173 261 2332 2766
3. Finland (collected 1997–8)
Age Negative
Low
positive Positive Total
0 74 4 4 82
1 59 0 60 119
2 2 1 77 80
3 3 1 71 75
4 2 1 80 83
5 1 2 86 89
6 2 1 72 75
7 4 1 67 72
8 1 1 63 65
9 2 2 92 96
10 2 9 74 85
11 1 4 94 99
12 1 2 55 58
13 0 1 59 60
14 2 6 56 64
15 2 9 76 87
16 3 7 88 98
17 2 6 93 101
18 2 1 99 102
19 3 4 98 105
20–24 3 11 183 197
3. Finland (collected 1997–8) continued
Age Negative
Low
positive Positive Total
25–29 4 1 194 199
30–34 2 0 199 201
35–39 2 1 199 202
40–49 2 0 200 202
50–59 0 1 199 200
60fi 0 0 203 203
Total 181 77 2841 3099
4. France (collected 1998)
Age Negative
Low
positive Positive Total
0 34 1 9 44
1 27 2 36 65
2 11 2 48 61
3 5 0 61 66
4 4 6 57 67
5 8 5 55 68
6 5 5 49 59
7 6 6 42 54
8 7 8 40 55
9 3 5 50 58
10 3 6 49 58
11 5 7 44 56
12 3 4 41 48
13 2 4 49 55
14 3 5 49 57
15 7 2 57 66
16 4 4 57 65
17 1 0 74 75
18 3 1 76 80
19 1 4 73 78
20–24 3 7 185 195
25–29 3 6 186 195
30–34 3 3 189 195
35–39 0 3 185 188
40–49 0 2 231 233
50–59 0 1 223 224
60› 2 2 410 414
Total 153 101 2625 2879
5. Netherlands (collected 1995–6)
Age Negative
Low
positive Positive Total
0 388 94 141 623
1 113 2 135 250
2 5 2 181 188
3 12 5 211 228
4 6 7 143 156
5 3 9 94 106
6 5 12 107 124
7 5 11 86 102
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5. Netherlands (collected 1995–6) Continued
Age Negative
Low
positive Positive Total
8 8 13 109 130
9 5 10 82 97
10 2 16 97 115
11 4 10 98 112
12 4 19 102 125
13 5 31 91 127
14 7 15 80 102
15 6 20 82 108
16 3 14 79 96
17 7 10 85 102
18 6 15 61 82
19 9 15 43 67
20–24 20 40 280 340
25–29 2 7 368 377
30–34 7 4 423 434
35–39 5 497 502
40–49 2 20 927 949
50–59 2 11 982 995
60› 1 22 1643 1666
Total 637 439 7227 8303
6. Italy (collected 1996–7)
Age Negative
Low
positive Positive Total
0 48 3 37 88
1 72 2 25 99
2 34 3 71 108
3 35 2 75 112
4 32 2 85 119
5 40 7 64 111
6 26 8 73 107
7 28 6 73 107
8 20 6 84 110
9 21 0 85 106
10 18 4 86 108
11 15 1 86 102
12 20 0 90 110
13 14 2 83 99
14 14 0 87 101
15 14 1 90 105
16 16 1 85 102
17 13 1 90 104
18 13 3 98 114
19 8 0 92 100
20–24 14 3 234 251
25–29 9 0 188 197
30–34 8 1 179 188
35–39 5 1 193 199
40–49 1 1 203 205
50–59 2 0 209 211
60› 5 0 199 204
Total 545 58 2964 3567
7. Germany (collected 1996)
Age Negative
Low
positive Positive Total
0 133 17 103 253
1 163 1 45 209
2 56 2 117 175
3 48 3 136 187
4 24 3 165 192
5 22 1 192 215
6 18 5 194 217
7 19 7 189 215
8 17 18 177 212
9 20 14 160 194
10 9 11 162 182
11 19 5 145 169
12 25 11 143 179
13 11 10 138 159
14 13 8 132 153
15 16 9 147 172
16 9 10 147 166
17 6 4 127 137
18 6 1 120 127
19 4 6 112 122
20–24 11 8 247 266
25–29 4 0 211 215
30–34 1 0 206 207
35–39 2 0 192 194
40–49 2 0 213 215
50–59 2 0 193 195
60› 0 0 225 225
Total 660 154 4338 5152
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